172 related articles for article (PubMed ID: 24549646)
1. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
2. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.
Li H; Chen X; Calhoun-Davis T; Claypool K; Tang DG
Cancer Res; 2008 Mar; 68(6):1820-5. PubMed ID: 18339862
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
[TBL] [Abstract][Full Text] [Related]
5. Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model.
Kumano M; Miyake H; Terakawa T; Furukawa J; Fujisawa M
BJU Int; 2010 Jul; 106(1):121-7. PubMed ID: 19912186
[TBL] [Abstract][Full Text] [Related]
6. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line.
Rowehl RA; Crawford H; Dufour A; Ju J; Botchkina GI
Cancer Genomics Proteomics; 2008; 5(6):301-10. PubMed ID: 19287071
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
Brimo F; Vollmer RT; Friszt M; Corcos J; Bismar TA
BJU Int; 2010 Aug; 106(3):418-23. PubMed ID: 20002675
[TBL] [Abstract][Full Text] [Related]
8. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential.
Darini CY; Pisani DF; Hofman P; Pedeutour F; Sudaka I; Chomienne C; Dani C; Ladoux A
Oncogene; 2012 May; 31(19):2438-49. PubMed ID: 21927026
[TBL] [Abstract][Full Text] [Related]
9. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.
Zeng Y; Wodzenski D; Gao D; Shiraishi T; Terada N; Li Y; Vander Griend DJ; Luo J; Kong C; Getzenberg RH; Kulkarni P
Cancer Res; 2013 Jul; 73(13):4123-33. PubMed ID: 23667174
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
12. Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers.
Grotenhuis BA; Dinjens WN; Wijnhoven BP; Sonneveld P; Sacchetti A; Franken PF; van Dekken H; Tilanus HW; van Lanschot JJ; Fodde R
J Pathol; 2010 Aug; 221(4):379-89. PubMed ID: 20549647
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells.
Itoh T; Terazawa R; Kojima K; Nakane K; Deguchi T; Ando M; Tsukamasa Y; Ito M; Nozawa Y
Free Radic Res; 2011 Sep; 45(9):1033-9. PubMed ID: 21682664
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.
Civenni G; Malek A; Albino D; Garcia-Escudero R; Napoli S; Di Marco S; Pinton S; Sarti M; Carbone GM; Catapano CV
Cancer Res; 2013 Nov; 73(22):6816-27. PubMed ID: 24063893
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
Wen X; Li X; Liao B; Liu Y; Wu J; Yuan X; Ouyang B; Sun Q; Gao X
Urology; 2009 Jun; 73(6):1407-11. PubMed ID: 19362342
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay.
Nishida S; Hirohashi Y; Torigoe T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T; Sato N
J Urol; 2012 Jul; 188(1):294-9. PubMed ID: 22608744
[TBL] [Abstract][Full Text] [Related]
19. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Bansal N; Bartucci M; Yusuff S; Davis S; Flaherty K; Huselid E; Patrizii M; Jones D; Cao L; Sydorenko N; Moon YC; Zhong H; Medina DJ; Kerrigan J; Stein MN; Kim IY; Davis TW; DiPaola RS; Bertino JR; Sabaawy HE
Clin Cancer Res; 2016 Dec; 22(24):6176-6191. PubMed ID: 27307599
[TBL] [Abstract][Full Text] [Related]
20. Sustained Early Disruption of Mitochondrial Function Contributes to Arsenic-Induced Prostate Tumorigenesis.
Singh B; Kulawiec M; Owens KM; Singh A; Singh KK
Biochemistry (Mosc); 2016 Oct; 81(10):1089-1100. PubMed ID: 27908234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
